CLSN Celsion Corporation

1.52
-0.05  -3%
Previous Close 1.57
Open 1.58
Price To Book 1.77
Market Cap 34,588,843
Shares 22,755,818
Volume 179,078
Short Ratio
Av. Daily Volume 203,603
Stock charts supplied by TradingView

NewsSee all news

  1. Celsion's New Subsidiary in China to Serve as Beachhead for Commercializing ThermoDox® in China and Southeast Asia

    Memorandum of Understanding completed with Chinese government officials in the Yuhang district of Hangzhou, China's biotech hub, to develop and commercialize innovative cancer therapies starting with ThermoDox®.Agreement

  2. Celsion Receives $2.0 Million Allocation Through the New Jersey Technology Business Tax Certificate Transfer (NOL) Program

     Non-Dilutive Funding Strengthens Balance Sheet; Proceeds Equate to More Than $0.08 Per Share Assures Funding Through Major Company Events; Company Provides Guidance on the Timing of Upcoming Development Milestones

  3. Celsion Corporation Reports Third Quarter 2019 Financial Results and Provides Business Update

    Independent Data Monitoring Committee (iDMC) Unanimously Recommends Continuation of Phase III OPTIMA Study at First Pre-Planned Efficacy AnalysisIndependent Data Safety Monitoring Board (DSMB) Unanimously Recommends

  4. Celsion Announces Publication of Research on Fluorescence Imaging of ThermoDox® Uptake in International Journal of Hyperthermia

    Independent Analysis Confirms Increasing Heating Time + ThermoDox® Improves Tumor Uptake of Drug, which may be visualized by real-time fluorescence imaging Study Confirms that ThermoDox® Can Deliver Doxorubicin in

  5. Celsion Corporation to Hold Third Quarter 2019 Financial Results Conference Call on Friday, November 15, 2019

    Company to Provide Clinical Development Update on its Phase III OPTIMA Study in Primary Liver Cancer and its Phase I/II OVATION 2 Study in Ovarian Cancer LAWRENCEVILLE, N.J., Nov. 08, 2019 (GLOBE NEWSWIRE) -- Celsion

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 3 interim efficacy November 4, 2019 - trial to continue as planned. Second analysis 2Q 2020.
ThermoDox - OPTIMA
Hepatocellular carcinoma - liver cancer
Phase 1/2 data due 4Q 2019. Moved to 1Q 2020 due to no update.
GEN-1 OVATION 2
Ovarian cancer
Final data released December 2015
ThermoDox - Dignity
Recurrent Chest Wall Breast Cancer (RCWBC)
Phase 1b PFS data released October 24, 2018 - PFS of 17.1 months in ITT population.
GEN-1 OVATION 1
Ovarian cancer

Latest News

  1. Celsion's New Subsidiary in China to Serve as Beachhead for Commercializing ThermoDox® in China and Southeast Asia

    Memorandum of Understanding completed with Chinese government officials in the Yuhang district of Hangzhou, China's biotech hub, to develop and commercialize innovative cancer therapies starting with ThermoDox®.Agreement

  2. Celsion Receives $2.0 Million Allocation Through the New Jersey Technology Business Tax Certificate Transfer (NOL) Program

     Non-Dilutive Funding Strengthens Balance Sheet; Proceeds Equate to More Than $0.08 Per Share Assures Funding Through Major Company Events; Company Provides Guidance on the Timing of Upcoming Development Milestones

  3. Celsion Corporation Reports Third Quarter 2019 Financial Results and Provides Business Update

    Independent Data Monitoring Committee (iDMC) Unanimously Recommends Continuation of Phase III OPTIMA Study at First Pre-Planned Efficacy AnalysisIndependent Data Safety Monitoring Board (DSMB) Unanimously Recommends

  4. Celsion Announces Publication of Research on Fluorescence Imaging of ThermoDox® Uptake in International Journal of Hyperthermia

    Independent Analysis Confirms Increasing Heating Time + ThermoDox® Improves Tumor Uptake of Drug, which may be visualized by real-time fluorescence imaging Study Confirms that ThermoDox® Can Deliver Doxorubicin in

  5. Celsion Corporation to Hold Third Quarter 2019 Financial Results Conference Call on Friday, November 15, 2019

    Company to Provide Clinical Development Update on its Phase III OPTIMA Study in Primary Liver Cancer and its Phase I/II OVATION 2 Study in Ovarian Cancer LAWRENCEVILLE, N.J., Nov. 08, 2019 (GLOBE NEWSWIRE) -- Celsion

  6. Celsion Announces DSMB Recommendation to Continue GEN-1 at 100mg/m² Dose to Complete the Phase I Portion of OVATION 2 Study in Ovarian Cancer

    GEN-1 Manufacturing Technology Transfer Successfully Produces High-Quality Affordable Investigational Product for Use in Clinical Trials LAWRENCEVILLE, N.J., Nov. 05, 2019 (GLOBE NEWSWIRE) -- Celsion

  7. Celsion Reports Unanimous Independent Data Monitoring Committee Recommendation to Continue the Phase III OPTIMA Study of ThermoDox® in Primary Liver Cancer

    The Data Monitoring Committee Signals that Patient Safety Data and Data Quality Meets Expectations and Company is to Proceed to Next Interim Analysis.The Pooled Progression-Free Survival (PFS) Data is Consistent with

  8. Celsion Strengthens Its 2019 Balance Sheet with the Approval of Its Application to Sell Net Operating Losses for $2.1 Million in Non-Dilutive Funding

     $2 Million in Additional NOL Sales are Available to the Company in 2020 Funding Through the New Jersey Technology Business Tax Certificate Transfer (NOL) Program LAWRENCEVILLE, N.J., Oct. 01, 2019 (GLOBE

  9. Celsion to Present at the Chardan 3rd Annual Genetic Medicines Conference

    LAWRENCEVILLE, N.J., Sept. 30, 2019 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ:CLSN), an oncology drug-development company, announces that Michael Tardugno, Chairman, President and Chief Executive Officer and

  10. Celsion Co-sponsors Hepatocellular Carcinoma Symposium at the International Liver Cancer Association (ILCA) Annual Conference

    LAWRENCEVILLE, N.J., Sept. 23, 2019 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ:CLSN), an oncology drug-development company, announces it co-sponsored a symposium focused on hepatocellular carcinoma (HCC) at the

  11. Celsion Announces Publication of Findings from Single-Site Study in China of ThermoDox® Plus RFA in the Journal of Cancer Research and Therapeutics

    Data show overall survival improvement of 22.5 months with ThermoDox® plus RFA of 45 minutes or longer Data provides additional corroboration of ThermoDox's potential for superior efficacy when combined with a